Progeria Quick Facts

Progeria Quick Facts

 

 
Home » About PRF » Quick Facts

Quick Facts

MISSION: To Discover Treatments and the Cure for Hutchinson-Gilford Progeria Syndrome and its Aging-related Disorders

PRF BY THE NUMBERS as of June 30, 2014

      • Identified children living with Progeria: 118* in 41 countries
      • PRF-sponsored Progeria Clinical Drug Trials: 3
      • Grants funded: 55, totaling over $5.5 million
      • Cell lines in the PRF Cell & Tissue Bank:  193
      • Children in PRF’s Medical & Research Database:  127
      • International Scientific Meetings on Progeria: 11
      • Number of languages into which PRF’s program and medical care materials are translated:  26
      • Increase in scientific publications since the Progeria gene discovery: 2,000%

        *Includes 24 children in the Progeroid Laminopathy category that have a mutation in the Lamin pathway, but do not produce progerin.

      What is Progeria?

      Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is a rare, fatal genetic condition of accelerated aging in children. Children with Progeria die of the same heart disease affects millions of normal aging adults (arteriosclerosis), but at an average age of just 14 years. Remarkably, their intellect is unaffected, and despite significant physical changes in their young bodies, these extraordinary children are intelligent, courageous, and full of life.  

      What is PRF?

      The Progeria Research Foundation (PRF) was established in 1999 by the parents of a child with Progeria, Drs. Leslie Gordon and Scott Berns,  and many dedicated friends and family who saw the need for a medical research resource for the doctors, patients, and families of those with Progeria.  Since that time, PRF has been the driving force behind the Progeria gene discovery and the first-ever Progeria drug treatment. PRF has developed programs and services to aid those affected by Progeria and the scientists that conduct Progeria research.  Today, PRF is the only non-profit organization solely dedicated to finding treatments and the cure for Progeria. PRF is hailed as a prime example of a successful translational research organization, moving from creation, to gene discovery, to first-ever drug treatment in just 13 years.

      Total Dollars Raised

      1999 through June 2014: $17,737,441

      85% of PRF’s annual expenses are consistently dedicated to its programs and services.

      The support we have received made the Progeria gene discovery, the Progeria clinical trials and all of our other extraordinary progress possible.  With the help of current and new supporters, we will win this race against time and find treatments and the cure for these special children. Moreover, Progeria discoveries are teaching us about the heart disease and the aging that affects us all.

      PRF’S PROGRAMS & SERVICES

        • First-Ever Progeria Clinical Drug Trials and Treatment:  PRF-Sponsored Clinical Drug Trials bring children from around the world for promising treatments that may help to improve disease, and may even extend the lives of children with Progeria. In 2012, history was made with the discovery that a farnesyltransferase inhibitor, or FTI, is the first-ever treatment for Progeria, and more recent studies conclude FTIs extend estimated lifespan - remarkable steps forward in the pursuit of a cure. PRF continues to explore other promising drugs, and is currently expanding the FTI trial so all children with Progeria can participate and have access to a drug that may give them longer, healthier lives. 

        • PRF’s International Progeria Registry  maintains centralized information on children and families living with Progeria.  This assures rapid distribution of any new information that may benefit the children. 
        • Cell & Tissue Bank: PRF’s Bank provides researchers with genetic and biological material from Progeria patients and their families, so research on Progeria and other aging-related diseases can be performed to bring us closer to the cure.  PRF has collected an impressive 193 cell lines from affected children worldwide (ages 2 months to 17 years) and 71 lines from their immediate relatives, including 9 Induced Pluripotent Stem Cell (iPSC) lines.
              • Medical & Research Database: The Database is a centralized collection of medical information from Progeria patients worldwide.  The data is rigorously analyzed to help us understand more about Progeria and devise treatment recommendations. In 2010, this analysis contributed to PRF’s comprehensive healthcare Handbook on Progeria aimed at optimizing quality of life. The Handbook is available in English, Spanish and Portuguese, Russian & Italian.
              • Diagnostic Testing: This program was developed in the wake of the 2003 gene discovery so that children, their families and medical caretakers can get a definitive, scientific diagnosis.  This can translate into earlier diagnosis, fewer misdiagnoses and early medical intervention to ensure a better quality of life for the children.
                • Scientific Workshops on Progeria: PRF has organized 11 scientific conferences that have brought together scientists and clinicians from all over the world to share their expertise and cutting edge scientific data, and foster collaboration in the fight against this devastating disease.
                      • Research Grants: Through peer review by our volunteer Medical Research Committee, PRF has funded projects throughout the world that have led to important discoveries about Progeria, heart disease and aging. Awards of up to $100,000 per year, for up to three years, have allowed innovative new research in Progeria to thrive. 
                            • Publications and Research: Both clinical and basic scientists have utilized the PRF grants, cells and tissues, and database; their discoveries are published in top-notch scientific journals.  The average annual number of scientific publications on Progeria since 2002 is more than 20 times that of the previous 50 years!
                              • PRF Translation Program: In touch with the world.  With a prominent global presence, PRF eliminates barriers to communication for patients and their families around the world.  This initiative has succeeded in translating PRF program and medical care materials into 26 different languages.

                              • Public Awareness: ProgeriaResearch.org provides access to the latest information on Progeria research and support for families, and through Facebook, Twitter and other mediums, PRF’s direct social media reach is nearly 600,000. PRF’s story has appeared on CNN, The Dr. Oz Show, Primetime, Dateline, The Katie Couric Show, and The Today Show, in Time and People magazines, The New York Times, The Wall Street Journal and many other widely-read media outlets. The award-winning 2013 HBO film Life According to Sam has brought awareness to a new level. PRF and partner GlobalHealthPR also manage a global awareness campaign called Find the Other 150, to further PRF’s efforts to find children with Progeria worldwide so they can get the unique help they need. The award-winning 2013 HBO film Life According to Sam has brought awareness to a new level. PRF and partner GlobalHealthPR also manage a global awareness campaign called Find the Other 150, to further PRF’s efforts to find children with Progeria worldwide so they can get the unique help they need.

                                WHO’S WHO AT PRF?

                                Audrey Gordon, Esq., President and Executive Director, Co-Founder
                                Working closely with the Board of Directors, officers, staff and volunteers, Ms. Gordon is responsible for ensuring The Progeria Research Foundation's financial growth, program development, and day-to-day management. 

                                Leslie B. Gordon, MD, PhD, Medical Director, Co-Founder
                                Dr. Gordon co-founded PRF with friends and family after her son, Sam, was diagnosed with Progeria. Dr. Gordon oversees PRF’s research-related programs, and is a co-chair for the Progeria clinical drug trials.  She is an Associate Professor of Pediatrics Research at the Warren Alpert Medical School of Brown University and Hasbro Children’s Hospital in Providence, RI, and a Staff Scientist at Boston Children’s Hospital and Harvard Medical School.  

                                Scott D. Berns, MD, MPH, FAAP, PRF Chairman of the Board, Co-Founder
                                Dr. Berns, Sam’s father, is a co-founder of The Progeria Research Foundation and serves as Chairman of the Board.  He is a Board Certified Pediatrician and Clinical Professor of Pediatrics at the Alpert Medical School of Brown University.  He is also Deputy Medical Director and Senior Vice President of Chapter Programs at the March of Dimes.

                                Tina, Brandon, Brittany and Zach Pickard, PRF’s Ambassador Family
                                The family of 5-year-old Zach lives in Lexington, Kentucky, and is an integral part of PRF’s efforts to raise public awareness, involve other families in our programs, and raise funds for research.  We appreciate the time and effort they devote to these important activities. 

                                quick links

                                Donate Now
                                Now more than ever, your contribution makes a difference.